Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 7,67 € (+104,53 %). Medianen er 4,31 € (+14,93 %).
| Køb |
10 |
| Behold |
6 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Deadline for Lilly offer to Adverum ends – liquidity risks in focus
Adverum is urging shareholders to accept Eli Lilly’s takeover offer by December 8, 2025. Lilly is offering $3.56 per share in cash plus a non-transferable earn‑out right that can provide additional payments of up to $8.91 depending on milestones. Adverum is under significant liquidity pressure (Current Ratio 0.65, EBITDA -$186.22 million) and has already received a $40 million promissory note from Lilly; a further $25 million is scheduled for December 5. The board views the offer as the best alternative to imminent liquidation, but the takeover requires the tendering of a majority of shares and customary closing conditions. » Mere på de.investing.com
Adverum accelerates recruitment for phase-3 trial of gene therapy for wet AMD
Adverum plans to complete patient enrollment for the approval‑relevant phase‑3 ARTEMIS trial earlier than planned and now expects full enrollment in Q4 2025 instead of Q1 2026. Due to the accelerated recruitment, the company is targeting publication of topline results in Q1 2027. The study is testing Ixo‑vec as a one‑time intravitreal treatment versus aflibercept; Ixo‑vec has received multiple regulatory acceleration designations. Financials continue to show high cash burn and a negative adjusted EBITDA of −$172 million; analyst price targets range from $3 to $33, and Mizuho cut its target to $12 while maintaining an Outperform rating. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2025 | |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | -396,24 t | - |
| Nettoresultat | -40,61 mio. | - |
| EBITDA | -40,21 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 82,96 mio. € |
Antal aktier | 22,08 mio. |
Højeste/laveste i 52 uger | 5,23 € - 1,53 € |
| Udbytte | Nej |
Beta | 0,87 |
P/E (PE Ratio) | -0,66 |
PEG (PEG Ratio) | 0,01 |
K/I (PB Ratio) | -1,84 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Adverum Biotechnologies, Inc. ist ein Gentherapie-Unternehmen im klinischen Stadium und entwickelt Gentherapie-Produktkandidaten zur Behandlung von Augenkrankheiten und seltenen Krankheiten. Der führende Produktkandidat ist ADVM-022, ein Gentherapiekandidat zur einmaligen intravitrealen Injektion für die Behandlung von Patienten mit chronischer Netzhauterkrankung, einschließlich feuchter altersbedingter Makuladegeneration und diabetischem Makulaödem. Adverum Biotechnologies, Inc. hat Lizenz- und Kooperationsvereinbarungen mit der University of California, der Cornell University, GenSight, Lexeo und Virovek. Das Unternehmen war früher unter dem Namen Avalanche Biotechnologies, Inc. bekannt und änderte im Mai 2016 seinen Namen in Adverum Biotechnologies, Inc. Adverum Biotechnologies, Inc. wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Redwood City, Kalifornien.
| Navn | Adverum Biotechnologies |
| CEO | Laurent Fischer |
| Hjemsted | Redwood City,
ca USA |
| Websted | |
| Sektor | Dagligvarer |
| Branche | Fødevarer |
| Børsnotering | 31.07.2014 |
| Medarbejdere | 155 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ADVM |
